Correlation between RUNX3 Expression and Gastric Cancer Risks: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LIU Qingqing ¹ , WANG Lijing ¹ , WANG Chao ¹ , ZHANG Chi ¹ ,  LIU Fen ^1,2

1. School of Public Health, Capital Medical University, Beijing 100069, China;2. Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing 100069, China;

Corresponding author：

LIU Fen, Email: liufen05@ccmu.edu.cn

Keywords：

RUNX3; Gastric cancer; Systematic review; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20130074

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To investigate the correlation between RUNX3 expression and human gastric cancer, as well as its clinically pathologic features.
Methods 　Such databases as PubMed, EMbase, VIP, WanFang Data and CBM were searched from their inception to February 28th, 2013 to collect case-control studies about the correlation between RUNX3 expression and human gastric cancer, as well as its clinically pathologic features, and the relevant references of the included literature were also retrieved. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data, and assessed the methodological quality. Then meta-analysis was conducted using RevMan 5.0 software.
Results 　A total of 6 case-control studies were included, which included 405 cases in the gastric cancer group and 185 cases in the normal gastric mucosa group. The results of meta-analysis showed that, RUNX3 expression was lower in the gastric cancer group than the normal gastric mucosa group, with a significant difference (OR=0.07, 95%CI 0.04 to 0.12, P lt;0.000 01); it was also lower in the subgroup of gastric cancer accompanied with lymph node metastasis than that without lymph node metastasis (OR=0.37, 95%CI 0.23 to 0.61, P lt;0.000 1); but it was higher in the subgroup of gastric cancer that had infiltrated into serosa than that had not, with a significant difference (OR=3.92, 95%CI 2.29 to 6.71, P lt;0.000 01); and it was also higher in the subgroup of well differentiated gastric cancer that the moderately and poorly differentiated, with a significant difference (OR=0.36, 95%CI 0.22 to 0.58, P lt;0.000 1).
Conclusion 　RUNX3 expression is notably correlated to gastric cancer and its clinically pathologic features. For the quantity and quality limitation of the included studies, this conclusion still needs to be further proved by performing more high quality studies.

Citation： LIU Qingqing,WANG Lijing,WANG Chao,ZHANG Chi,LIU Fen. Correlation between RUNX3 Expression and Gastric Cancer Risks: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2013, 13(4): 431-435. doi: 10.7507/1672-2531.20130074 Copy

1.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2.	唐巍峰, 孙斌, 顾海勇, 等. COX-2基因多态性与食管癌易感性关系的Meta分析. 中国循证医学杂志, 2011, 11(12): 1391-1394.
3.	许丽娜, 刘芬, 杨兴华, 等. 宫颈癌及其不同临床病理特征中COX-2表达的Meta分析.中国循证医学杂志, 2010, 10(3): 346-351.
4.	Bangsow C, Rubins N, Glusman G, et al. TheRUNX3 gene-sequence, structure and regulated expression. Gene, 2001, 279(2): 221-232.
5.	Li QL , Ito K, Sakakura C, et al. Causal relationship betweenthe loss of RUNX3 expression and gastric cancer. Cell, 2002, 109(1): 113-124.
6.	Lau QC, Raja E, Salto-tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res, 2006, 66(13): 6512-6520.
7.	Takahashi T, Shivapurkar N, Riquelme E, et al. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res, 2004, 10(18 Pt1): 6126-6133.
8.	Bae SC, Choi JK. Tumor suppressor activity of RUNX3. Oncogene, 2004, 23(24): 4336-4340.
9.	曾超, 贺修胜, 罗桥, 等. 胃癌中RUNX3蛋白表达与胃癌关系的研究. 癌变畸变突变, 2005, 18(6): 455-458.
10.	姜威, 姚海涛, 颜玉, 等. 胃癌组织中RUNX3基因的蛋白表达研究. 黑龙江医药科学, 2011, 34(4): 80-81.
11.	刘九思, 王梦龙. 胃癌中Runx3表达及其甲基化. 江西医学院学报, 2009, 49(2): 103-105.
12.	Wells G A, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics. 2000.
13.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 2010, 25(9): 603-605.
14.	李利义. 胃癌中Runx3基因启动子甲基化及其蛋白表达研究. 浙江大学医学院, 硕士研究生论文, 2007.
15.	雷兰英, 杨桂芳, 张振东, 等. RUNX3、SMAD4、VEGF在人胃癌中的表达及意义. 武汉大学学报(医学版), 2010, 31(4): 451-454.
16.	姜帆, 孟紫蔽, 孙建国. 胃癌中RUNX3、β-catenin和E-cadherin表达的关系. 广东医学, 2012, 33(9): 1291-1294.
17.	赵永勋, 李玉民, 关泉林, 等. 幽门螺杆菌感染对胃癌组织Runx3、iNOS蛋白表及患者生存率的影响. 中国老年学杂志, 2012, 32(20): 4396-2398.
18.	杨振宇, 李卉, 王强. 胃癌组织中RUNX3的表达与c-Met的相关性研究. 现代肿瘤医学, 2011, 19(1): 85-88.
19.	李华. 胃癌组织中RUNX3和突变型P53蛋白的表达及临床意义. 河北医药, 2012, 34(1): 52-53.
20.	Taniuchi I, Osato M, Egawa T, et al. Differential requirements for Runx proteins in CD4 repressionand epigenetic silencing during T lymphocyte development. Cell, 2002, 111(5): 621-633.
21.	Osaki M, Moriyama M, Adachi K, et al. Expresion of RUNX3 protein in human gastric mucosa, intestinal metaplasia and carcinoma. Eur J Clin Invest, 2004, 34(9): 605-612.
22.	Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res, 2005, 65(11): 4809-4816.
23.	成秀梅, 冯一中. Runx3、Sp1、Bcl-2在胃腺癌中的表达及对预后的影响. 山东医药, 2010, 50(24): 48-49.
24.	宋国庆, 王强. Survivin和Runx3蛋白在胃癌组织中的表达及其临床意义. 现代肿瘤医学, 2011, 19(4): 721-723.

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2. 唐巍峰, 孙斌, 顾海勇, 等. COX-2基因多态性与食管癌易感性关系的Meta分析. 中国循证医学杂志, 2011, 11(12): 1391-1394.
3. 许丽娜, 刘芬, 杨兴华, 等. 宫颈癌及其不同临床病理特征中COX-2表达的Meta分析.中国循证医学杂志, 2010, 10(3): 346-351.
4. Bangsow C, Rubins N, Glusman G, et al. TheRUNX3 gene-sequence, structure and regulated expression. Gene, 2001, 279(2): 221-232.
5. Li QL , Ito K, Sakakura C, et al. Causal relationship betweenthe loss of RUNX3 expression and gastric cancer. Cell, 2002, 109(1): 113-124.
6. Lau QC, Raja E, Salto-tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res, 2006, 66(13): 6512-6520.
7. Takahashi T, Shivapurkar N, Riquelme E, et al. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res, 2004, 10(18 Pt1): 6126-6133.
8. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. Oncogene, 2004, 23(24): 4336-4340.
9. 曾超, 贺修胜, 罗桥, 等. 胃癌中RUNX3蛋白表达与胃癌关系的研究. 癌变畸变突变, 2005, 18(6): 455-458.
10. 姜威, 姚海涛, 颜玉, 等. 胃癌组织中RUNX3基因的蛋白表达研究. 黑龙江医药科学, 2011, 34(4): 80-81.
11. 刘九思, 王梦龙. 胃癌中Runx3表达及其甲基化. 江西医学院学报, 2009, 49(2): 103-105.
12. Wells G A, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics. 2000.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 2010, 25(9): 603-605.
14. 李利义. 胃癌中Runx3基因启动子甲基化及其蛋白表达研究. 浙江大学医学院, 硕士研究生论文, 2007.
15. 雷兰英, 杨桂芳, 张振东, 等. RUNX3、SMAD4、VEGF在人胃癌中的表达及意义. 武汉大学学报(医学版), 2010, 31(4): 451-454.
16. 姜帆, 孟紫蔽, 孙建国. 胃癌中RUNX3、β-catenin和E-cadherin表达的关系. 广东医学, 2012, 33(9): 1291-1294.
17. 赵永勋, 李玉民, 关泉林, 等. 幽门螺杆菌感染对胃癌组织Runx3、iNOS蛋白表及患者生存率的影响. 中国老年学杂志, 2012, 32(20): 4396-2398.
18. 杨振宇, 李卉, 王强. 胃癌组织中RUNX3的表达与c-Met的相关性研究. 现代肿瘤医学, 2011, 19(1): 85-88.
19. 李华. 胃癌组织中RUNX3和突变型P53蛋白的表达及临床意义. 河北医药, 2012, 34(1): 52-53.
20. Taniuchi I, Osato M, Egawa T, et al. Differential requirements for Runx proteins in CD4 repressionand epigenetic silencing during T lymphocyte development. Cell, 2002, 111(5): 621-633.
21. Osaki M, Moriyama M, Adachi K, et al. Expresion of RUNX3 protein in human gastric mucosa, intestinal metaplasia and carcinoma. Eur J Clin Invest, 2004, 34(9): 605-612.
22. Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res, 2005, 65(11): 4809-4816.
23. 成秀梅, 冯一中. Runx3、Sp1、Bcl-2在胃腺癌中的表达及对预后的影响. 山东医药, 2010, 50(24): 48-49.
24. 宋国庆, 王强. Survivin和Runx3蛋白在胃癌组织中的表达及其临床意义. 现代肿瘤医学, 2011, 19(4): 721-723.

Chinese Journal of Evidence-Based Medicine

Correlation between RUNX3 Expression and Gastric Cancer Risks: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content